LOPID SIDE EFFECTS

  • Generic Name: gemfibrozil
  • Brand Name: Lopid
  • Drug Class: Fibric Acid Agents
Last updated on MDtodate: 10/7/2022

SIDE EFFECTS

In the double-blind controlled phase of the primary prevention component of the Helsinki Heart Study, 2046 patients received LOPID for up to five years. In that study, the following adverse reactions were statistically more frequent in subjects in the LOPID group:

 

LOPID
(N = 2046)
PLACEBO
(N = 2035)
Frequency in percent of subjects
Gastrointestinal reactions 34.2 23.8
  Dyspepsia 19.6 11.9
  Abdominal pain 9.8 5.6
  Acute appendicitis 1.2 0.6
  (histologically confirmed in most cases where data were available)
Atrial fibrillation 0.7 0.1
Adverse events reported by more than 1% of subjects, but without a significant difference between groups:
Diarrhea 7.2 6.5
Fatigue 3.8 3.5
Nausea/Vomiting 2.5 2.1
Eczema 1.9 1.2
Rash 1.7 1.3
Vertigo 1.5 1.3
Constipation 1.4 1.3
Headache 1.2 1.1

 

Gallbladder surgery was performed in 0.9% of LOPID and 0.5% of placebo subjects in the primary prevention component, a 64% excess, which is not statistically different from the excess of gallbladder surgery observed in the clofibrate group compared to the placebo group of the WHO study. Gallbladder surgery was also performed more frequently in the LOPID group compared to the placebo group (1.9% versus 0.3%, p=0.07) in the secondary prevention component. A statistically significant increase in appendectomy in the gemfibrozil group was seen also in the secondary prevention component (6 on gemfibrozil versus 0 on placebo, p=0.014).

Nervous system and special senses adverse reactions were more common in the LOPID group. These included hypesthesia, paresthesias, and taste perversion. Other adverse reactions that were more common among LOPID treatment group subjects but where a causal relationship was not established include cataracts, peripheral vascular disease, and intracerebral hemorrhage.

From other studies it seems probable that LOPID is causally related to the occurrence of MUSCULOSKELETAL SYMPTOMS, and to ABNORMAL LIVER FUNCTION TESTS and HEMATOLOGIC CHANGES.

Reports of viral and bacterial infections (common cold, cough, urinary tract infections) were more common in gemfibrozil treated patients in other controlled clinical trials of 805 patients. Additional adverse reactions that have been reported for gemfibrozil are listed below by system. These are categorized according to whether a causal relationship to treatment with LOPID is probable or not established:

 

CAUSAL RELATIONSHIP PROBABLE CAUSAL RELATIONSHIP NOT ESTABLISHED
General: weight loss
Cardiac: extrasystoles
Gastrointestinal: cholestatic jaundice pancreatitis
hepatoma
colitis
Central Nervous System: dizziness confusion
somnolence convulsions
paresthesia syncope
peripheral neuritis
decreased libido
depression
headache
Eye: blurred vision retinal edema
Genitourinary: impotence decreased male fertility
renal dysfunction
Musculoskeletal: myopathy
myasthenia
myalgia
painful extremities
arthralgia
synovitis
Clinical Laboratory: increased creatine phosphokinase positive antinuclear antibody
increased bilirubin
increased liver transaminases (AST, ALT)
increased alkaline phosphatase
Hematopoietic: anemia thrombocytopenia
leukopenia
bone marrow hypoplasia
eosinophilia
Immunologic: angioedema anaphylaxis
laryngeal edema Lupus-like syndrome
urticaria vasculitis
Integumentary: exfoliative dermatitis alopecia
rash photosensitivity
dermatitis
pruritus

 

Additional adverse reactions that have been reported include cholecystitis and cholelithiasis

 

SRC: NLM .